| ABL1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
- Regulation of actin dynamics for phagocytic cup formation
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- Myogenesis
- Myogenesis
- RHO GTPases Activate WASPs and WAVEs
- HDR through Single Strand Annealing (SSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Cyclin D associated events in G1
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- RUNX2 regulates osteoblast differentiation
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
|
- ATP
- Imatinib
- Dasatinib
- N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
- Nilotinib
- XL228
- Bosutinib
- 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
- Myristic acid
- 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
- 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
- 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
- Regorafenib
- Ponatinib
- Brigatinib
- Radotinib
|
- Chronic myeloid leukemia (CML)
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
| ABL2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
|
- ATP
- Dasatinib
- XL228
- 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE
|
|
| ACKR2 |
atypical chemokine receptor 2 |
- Chemokine receptors bind chemokines
|
|
|
| CAMP |
cathelicidin antimicrobial peptide |
- Neutrophil degranulation
- Antimicrobial peptides
|
|
|
| CISH |
cytokine inducible SH2 containing protein |
- Interleukin-7 signaling
- Neddylation
- Growth hormone receptor signaling
|
|
|
| EBNA1BP2 |
EBNA1 binding protein 2 |
- Major pathway of rRNA processing in the nucleolus and cytosol
|
|
|
| FAM9B |
family with sequence similarity 9 member B |
|
|
|
| IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
- Transcriptional activation of mitochondrial biogenesis
- Citric acid cycle (TCA cycle)
|
- Isocitric Acid
- Enasidenib
|
|
| ITGA9 |
integrin subunit alpha 9 |
- Integrin cell surface interactions
- Integrin cell surface interactions
- ECM proteoglycans
- Signal transduction by L1
|
|
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
|
| MAPK6 |
mitogen-activated protein kinase 6 |
|
|
|
| MLH1 |
mutL homolog 1 |
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Defective Mismatch Repair Associated With MLH1
- Defective Mismatch Repair Associated With PMS2
- TP53 Regulates Transcription of DNA Repair Genes
- Meiotic recombination
|
|
- Colorectal cancer
- Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
- Endometrial Cancer
- Ovarian cancer
|
| MST1R |
macrophage stimulating 1 receptor |
|
|
|
| RHOA |
ras homolog family member A |
- GPVI-mediated activation cascade
- Axonal growth inhibition (RHOA activation)
- Rho GTPase cycle
- PI3K/AKT activation
- Axonal growth stimulation
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- G beta:gamma signalling through PI3Kgamma
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- PCP/CE pathway
- G alpha (12/13) signalling events
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D induced cell migration and growth-cone collapse
- Sema4D induced cell migration and growth-cone collapse
- VEGFA-VEGFR2 Pathway
- RHO GTPases activate PKNs
- RHO GTPases activate CIT
- RHO GTPases activate CIT
- RHO GTPases activate KTN1
- RHO GTPases Activate ROCKs
- RHO GTPases Activate ROCKs
- RHO GTPases Activate Formins
- RHO GTPases Activate Rhotekin and Rhophilins
- RHO GTPases Activate Rhotekin and Rhophilins
- Ovarian tumor domain proteases
- ERBB2 Regulates Cell Motility
- Neutrophil degranulation
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- SLIT2:ROBO1 increases RHOA activity
|
|
|
| SELENBP1 |
selenium binding protein 1 |
|
|
|
| UQCRC1 |
ubiquinol-cytochrome c reductase core protein 1 |
- Respiratory electron transport
|
- 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol
- Myxothiazol
- 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole
- METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE
- (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE
- FAMOXADONE
- METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE
- 2-NONYL-4-HYDROXYQUINOLINE N-OXIDE
- UBIQUINONE-2
|
|